| 000 | 01832 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250513124627.0 | ||
| 264 | 0 | _c19970930 | |
| 008 | 199709s 0 0 eng d | ||
| 022 | _a0270-4137 | ||
| 024 | 7 |
_a10.1002/(sici)1097-0045(19970901)32:4<272::aid-pros7>3.0.co;2-l _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aTjoa, B A | |
| 245 | 0 | 0 |
_aFollow-up evaluation of prostate cancer patients infused with autologous dendritic cells pulsed with PSMA peptides. _h[electronic resource] |
| 260 |
_bThe Prostate _cSep 1997 |
||
| 300 |
_a272-8 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Clinical Trial, Phase I; Comparative Study; Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAlkaline Phosphatase _xblood |
| 650 | 0 | 4 | _aAmino Acid Sequence |
| 650 | 0 | 4 |
_aBiomarkers _xblood |
| 650 | 0 | 4 | _aCells, Cultured |
| 650 | 0 | 4 |
_aDendritic Cells _xtransplantation |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 | _aHematocrit |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunotherapy _xadverse effects |
| 650 | 0 | 4 | _aInfusions, Intravenous |
| 650 | 0 | 4 | _aLymphocyte Count |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aPeptide Fragments _xadministration & dosage |
| 650 | 0 | 4 |
_aProstate-Specific Antigen _xadministration & dosage |
| 650 | 0 | 4 |
_aProstatic Neoplasms _xtherapy |
| 650 | 0 | 4 | _aTime Factors |
| 650 | 0 | 4 | _aTransplantation, Autologous |
| 700 | 1 | _aErickson, S J | |
| 700 | 1 | _aBowes, V A | |
| 700 | 1 | _aRagde, H | |
| 700 | 1 | _aKenny, G M | |
| 700 | 1 | _aCobb, O E | |
| 700 | 1 | _aIreton, R C | |
| 700 | 1 | _aTroychak, M J | |
| 700 | 1 | _aBoynton, A L | |
| 700 | 1 | _aMurphy, G P | |
| 773 | 0 |
_tThe Prostate _gvol. 32 _gno. 4 _gp. 272-8 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/(sici)1097-0045(19970901)32:4<272::aid-pros7>3.0.co;2-l _zAvailable from publisher's website |
| 999 |
_c9267041 _d9267041 |
||